Dr David James Pinato is an NIHR Academic Clinical Lecturer in Medical Oncology working within the Division of Surgery and Cancer at Imperial College, London.
Since graduating in Medicine with highest honors at the University of Piemonte Orientale "A. Avogadro" in Novara, Italy, David devoted his research efforts to study the role of inflammation as a molecular mechanism underlying the pathogenesis and progression of Hepatocellular Carcinoma (HCC), the most frequently occurring primary liver tumor that currently ranks 5th by incidence and 3rd by mortality on a global scale. His studies, supported by international collaborations, eventually led to the qualification of novel prognostic and predictive biomarkers in HCC.
David completed his research training being awarded a Masters of Research in Translational Medicine and a Ph.D. in Clinical and Experimental Medicine under the joint supervision of Dr. Rohini Sharma (Imperial College, London) and Prof. Mario Pirisi (Novara, Italy). Whilst at Imperial as a research fellow and Ph.D. student he developed considerable experience in translational oncology within the specific setting of early phase clinical trials. As part of his ongoing collaboration with the academic pathology unit at Imperial, David devoted his research interests to the identification of novel biomarkers in thoracic malignancies (lung cancer and mesothelioma) and collaborated with the neuroendocrine tumor unit looking at tissue predictors of malignancy in phaeochromocytomas and gastrointestinal neuroendocrine tumors.
Since his graduation, David matured his clinical skills attending several academic institutions in Europe including the University Hospital in Zürich, the Medical University in Vienna and the University of Ioannina in Greece. He completed his core medical training across some of the busiest acute hospitals in London, being elected member of the Royal College of Physicians (MRCP) in 2014. He has trained in Medical Oncology as part of the Royal Marsden Hospital rotation, having migrated to Imperial College in April 2015 to take up his clinical lectureship. He has been awarded the European School of Oncology fellowship in 2008 and the Fulbright Visiting Research Scholar Fellowship for 2010/2011.
David's research efforts on biomarker discovery have been recognized with the prestigious Merit Award from the American Society of Clinical Oncology (ASCO) twice in 2016 and 2017 as well as the Sylvia Lawler Prize in Oncology from the Royal Society of Medicine in 2016. He lectures internationally in the field of molecular oncology with a specific interest in HCC and acts as a reviewer for a number of peer-reviewed journals including Hepatology, Journal of Hepatology, Oncogene, OncoImmunology and many others.
Pinato DJ, Newsom-Davis T, 2018, Regression of Paraneoplastic Rash after Lung Cancer Chemotherapy., J Thorac Oncol, Vol:13, Pages:139-140
et al., 2017, Review article: delivering precision oncology in intermediate-stage liver cancer, Alimentary Pharmacology & Therapeutics, Vol:45, ISSN:0269-2813, Pages:1514-1523
et al., 2017, Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib, Oncotarget, Vol:8, ISSN:1949-2553, Pages:36161-36170
et al., 2017, Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients, Blood, Vol:129, ISSN:0006-4971, Pages:2143-2147
et al., 2017, On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study, Alimentary Pharmacology & Therapeutics, Vol:45, ISSN:0269-2813, Pages:1146-1155